Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.
about
Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory AcceptancePredicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical ModelsRecent developments in using mechanistic cardiac modelling for drug safety evaluationPBPK modeling and simulation in drug research and developmentDrug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trialsPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationImpact of physiologically based pharmacokinetic models on regulatory reviews and product labels: Frequent utilization in the field of oncologyTranslational learning from clinical studies predicts drug pharmacokinetics across patient populations.Pharmacists in Australian general practice: an opportunity for expertise in precision medicineA Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to HumansGood Practices in Model-Informed Drug Discovery and Development: Practice, Application, and DocumentationTowards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.Physiologically Based Pharmacokinetic (Pbpk) Model of the Cyp2d6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications.Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.Commentary on the MID3 Good Practices Paper.Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.Facing the challenges of multiscale modelling of bacterial and fungal pathogen-host interactions.Performance Assessment and Translation of Physiologically Based Pharmacokinetic Models from acslX™ to Berkeley Madonna™, MATLAB®, and R language: Oxytetracycline and Gold Nanoparticles as Case Examples.Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.Opportunities to Apply the 3Rs in Safety Assessment Programs.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.Mathematical modeling and simulation in animal health - Part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment.Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success.Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).Intra-Target Microdosing (ITM): A Novel Drug Development Approach Aimed at Enabling Safer and Earlier Translation of Biological Insights Into Human Testing.Regulatory framework on bioequivalence criteria for locally acting gastrointestinal drugs: the case for oral modified release mesalamine formulations.Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach.Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery.Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models.Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK.Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.Physiologically based and population PK modeling in optimizing drug development: A predict-learn-confirm analysis.
P2860
Q26745824-00C39A04-C2FF-4516-9F48-58BA5D31EE26Q26764739-D1282EB9-23F7-4E11-BE65-596C08BA6C8EQ26764870-253BD37C-B507-4549-8462-F9E8DFDD0654Q28066513-97FD580C-26FF-4E34-AE80-900D9B51F7B6Q28071256-B56CB2FB-6A3D-44CF-91F5-01B30819FF13Q28088352-DF23B3FC-FA64-4D88-84FF-676FFAEE99BCQ33632130-E7B6B528-A436-4666-A615-D1C6BE996FB8Q33767468-F69035E3-8993-41CF-A07E-DBCB3D447FA4Q36114697-9BEBE3D3-A298-45E7-A9EB-096CC9093502Q36445112-22F852DB-155E-46EB-88FC-BF9490FD8723Q36734132-304150FF-37CD-4333-93DC-05CF37EB9304Q37126489-C478CAF9-6222-4D7F-9849-A24E2D3586E6Q37726177-72C388E7-731B-47C7-95D8-9B832F54F0E0Q37733479-C75AFBE3-2752-4470-938C-41015A01FCF1Q38599220-71AA62CE-3525-4FB6-AB0A-FEF896EAB2CAQ38605894-D9F636AD-09AB-4E71-A386-0845AA1973ABQ38687397-684CAB4D-318D-4628-A100-10BCA6FE384EQ38707591-C2886CE6-397D-4B31-9B65-50D5822EA2C7Q38719689-F974DD8A-3729-47D1-A7BD-A90655A8FB80Q38726901-10214ED6-8F37-481C-93B2-F4D0EC95DEF6Q38731345-DDFFDBC5-219C-4263-8CDA-057EB827E451Q38758820-8F44E81D-A5E7-4176-B3B4-AB7F001F6A13Q38768114-D35C76D8-5D1E-49DE-9E63-905DDE29CBB0Q38774773-47579E4E-E601-42AD-BB4F-EF4A7897B6D0Q38800092-B2EF2E1F-D827-4036-9AD4-6AC3B974F3A8Q38810378-ABFC0202-31BB-4BAE-98CB-EC95CDD97398Q38888255-5BEA34CA-7545-47B8-B40C-382A6235E281Q38958223-46E3D332-88C2-49B5-A717-B8113BD24C23Q38959281-3433AFA5-6FF5-469F-AD20-82516010ECDFQ39040977-B3865D47-1589-4A48-8356-AFE80C381558Q39178447-F001E931-4D1B-4F67-8A1E-5D72CB31E0E7Q39248701-75138530-D60C-4286-9721-D730627B2BD3Q39401950-46D05D06-F55F-40EA-88BD-058D1D134A92Q39548977-01773FBB-A225-41B9-98AA-4A4887B653E0Q39698362-9B64FA57-14F1-4D91-8842-7226FC984AF7Q39742601-B29A457B-D188-498D-A058-43210C9F88BEQ39830501-52B7DAF1-7ECB-4ACC-9237-D03131036763Q40606545-DAAAFC10-0D68-4D28-A6F2-DA8672C4F8ECQ40772216-CB5ECD9B-3110-4FD8-94E5-269BD2F91FB2Q40882268-39C720CC-CFE2-4C4C-BDDC-9A8579C5DA62
P2860
Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Physiologically based pharmaco ...... ceutical industry perspective.
@en
type
label
Physiologically based pharmaco ...... ceutical industry perspective.
@en
prefLabel
Physiologically based pharmaco ...... ceutical industry perspective.
@en
P2093
P2860
P356
P1476
Physiologically based pharmaco ...... ceutical industry perspective.
@en
P2093
S A Peters
T Heimbach
V V Upreti
P2860
P304
P356
10.1002/CPT.37
P407
P577
2015-01-09T00:00:00Z